Overview
- Located at Generation Park in northeast Houston, the API facility was selected from more than 300 proposals for its workforce, infrastructure and industrial ecosystem.
- The project secures an estimated $146 million through Texas’ Jobs, Energy, Technology and Innovation program plus a $5.5 million Texas Enterprise Fund grant.
- The site is expected to create about 615 permanent high‑wage roles and roughly 4,000 construction jobs, according to the company and state officials.
- Manufacturing will focus on the active ingredients for orforglipron—Lilly’s oral GLP‑1 candidate—along with small‑molecule therapies in oncology, immunology, cardiometabolic health and neuroscience, using AI, machine learning and digital automation.
- The Houston plant is the second of four new U.S. facilities in Lilly’s expansion; the first was confirmed in Virginia, two additional locations will be named later in 2025, and medicines are expected to be produced across the network within five years.